 |
424 Diseases |  |
809 Trials |
|
809 Trials |  |
14393 News |  |
| «12...168169170171172173174175176177178...235236» |
- | Avastin (bevacizumab) / Roche
Biomarker, Trial primary completion date: Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer (clinicaltrials.gov) - Jul 18, 2019
P3, N=3610, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2019 --> Mar 2020
- | Enrollment closed, Trial completion date, Trial primary completion date, Metastases: SEQUENCE: Phase I/II Study of Nab-paclitaxel and Gemcitabine Followed by AG-mFOLFOX in Patients With Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov) - Jul 18, 2019
P1/2, N=168, Active, not recruiting, Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Trial primary completion date: Jul 2019 --> Mar 2020 Recruiting --> Active, not recruiting | Trial completion date: Dec 2019 --> Apr 2020 | Trial primary completion date: May 2019 --> Apr 2020
- | Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Enrollment open, PD(L)-1 Biomarker, IO biomarker, Metastases: PRODIGE 59 - DURIGAST: Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Jul 18, 2019
P2, N=105, Recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
Recruiting --> Active, not recruiting | Trial completion date: Dec 2019 --> Apr 2020 | Trial primary completion date: May 2019 --> Apr 2020 Not yet recruiting --> Recruiting
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma (clinicaltrials.gov) - Jul 18, 2019
P2, N=66, Recruiting, Sponsor: Case Comprehensive Cancer Center
Not yet recruiting --> Recruiting Trial completion date: Apr 2019 --> Feb 2020 | Trial primary completion date: Apr 2019 --> Feb 2020
- | Enrollment change: Mature B-Cell Lymphoma And Leukemia Study III (clinicaltrials.gov) - Jul 18, 2019
P2/3, N=168, Recruiting, Sponsor: St. Jude Children's Research Hospital
Trial completion date: Apr 2019 --> Feb 2020 | Trial primary completion date: Apr 2019 --> Feb 2020 N=122 --> 168
- | Biomarker, Enrollment closed, Trial completion date, MSi-H Biomarker, PD(L)-1 Biomarker: MODUL: A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Jul 18, 2019
P2, N=1400, Active, not recruiting, Sponsor: Hoffmann-La Roche
N=122 --> 168 Suspended --> Active, not recruiting | Trial completion date: Dec 2021 --> Oct 2020
- | Rituxan (rituximab) / Roche
Enrollment closed, Combination therapy: Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma (clinicaltrials.gov) - Jul 17, 2019
P2, N=25, Active, not recruiting, Sponsor: University of Miami
Suspended --> Active, not recruiting | Trial completion date: Dec 2021 --> Oct 2020 Recruiting --> Active, not recruiting
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Enrollment open, Metastases: Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy (clinicaltrials.gov) - Jul 16, 2019
P1, N=20, Recruiting, Sponsor: Washington University School of Medicine
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, Opdivo (nivolumab) / BMS
Trial primary completion date: HCRN GI16-288: A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC (clinicaltrials.gov) - Jul 15, 2019
P2, N=78, Recruiting, Sponsor: Darren Carpizo, MD
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2019 --> Dec 2020
- | Trial primary completion date: QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy (clinicaltrials.gov) - Jul 15, 2019
P1/2, N=173, Active, not recruiting, Sponsor: NantKwest, Inc.
Trial primary completion date: Jun 2019 --> Dec 2020 Trial primary completion date: Dec 2018 --> Dec 2019
- | Trial primary completion date: QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed (clinicaltrials.gov) - Jul 15, 2019
P1/2, N=65, Active, not recruiting, Sponsor: NantKwest, Inc.
Trial primary completion date: Dec 2018 --> Dec 2019 Trial primary completion date: May 2019 --> Dec 2019
- | Trial completion date, Trial primary completion date: QUILT-3.080: NANT Pancreatic Cancer Vaccine (clinicaltrials.gov) - Jul 15, 2019
P1b/2, N=173, Active, not recruiting, Sponsor: NantKwest, Inc.
Trial primary completion date: May 2019 --> Dec 2019 Trial completion date: May 2020 --> Dec 2019 | Trial primary completion date: May 2019 --> Dec 2019
- | Opdivo (nivolumab) / BMS
New P2 trial: Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L) (clinicaltrials.gov) - Jul 15, 2019
P2, N=74, Recruiting, Sponsor: Weill Medical College of Cornell University
- | Trial completion, Metastases: FORTUNE: Neoadjuvant FOLFOXIRI Chemotherapy Alone for Locally Advanced Rectal Cancer (clinicaltrials.gov) - Jul 11, 2019
P2, N=84, Completed, Sponsor: Sun Yat-sen University
Trial completion date: May 2020 --> Dec 2019 | Trial primary completion date: May 2019 --> Dec 2019 Active, not recruiting --> Completed
- | leucovorin calcium / generics, fluorouracil / generics, paclitaxel / generics
Review, Journal: The current status of multimodality treatment for unresectable locally advanced esophageal squamous cell carcinoma. (Pubmed Central) - Jul 11, 2019
...dCRT regimens using 5-FU plus leucovorin plus oxaliplatin (FOLFOX), and carboplatin plus paclitaxel have been investigated in prospective clinical trials...Induction chemotherapy using docetaxel plus 5-FU plus cisplatin has also been under investigation...Immunotherapy in combination with radiotherapy has also gathered attention. For the establishment of new and effective treatments in the field of unresectable locally advanced ESCC, a collaboration between clinical researchers and basic researchers is warranted.
- | leucovorin calcium / generics
Clinical, Journal: Diabetic ketoacidosis caused by fulminant type 1 diabetes during adjuvant chemotherapy for colon cancer: A case report. (Pubmed Central) - Jul 10, 2019
Development of diabetic ketoacidosis (DKA) caused by fulminant type 1 diabetes (FT1D) during administration of uracil-tegafur (UFT) with leucovorin (LV) as adjuvant chemotherapy is extremely rare...Following admission, she was examined and diagnosed with FT1D. The present case describes an extremely rare case of DKA caused by FT1D during adjuvant chemotherapy with UFT + LV for colon cancer.
- | Opdivo (nivolumab) / BMS, Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Enrollment open: Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer (clinicaltrials.gov) - Jul 9, 2019
P1/2, N=40, Recruiting, Sponsor: University of Michigan Rogel Cancer Center
The present case describes an extremely rare case of DKA caused by FT1D during adjuvant chemotherapy with UFT + LV for colon cancer. Not yet recruiting --> Recruiting
- ||| oleclumab (MEDI9447) / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases: D6070C00005: MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study. (clinicaltrials.gov) - Jul 8, 2019
P1b/2, N=309, Recruiting, Sponsor: MedImmune LLC
Not yet recruiting --> Recruiting N=204 --> 309 | Trial completion date: Apr 2021 --> Nov 2021 | Trial primary completion date: Apr 2021 --> Nov 2021
- | Blincyto (blinatumomab) / Astellas, Amgen
Enrollment open: AALL1731: A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 7, 2019
P3, N=6720, Recruiting, Sponsor: National Cancer Institute (NCI)
N=204 --> 309 | Trial completion date: Apr 2021 --> Nov 2021 | Trial primary completion date: Apr 2021 --> Nov 2021 Not yet recruiting --> Recruiting
- | leucovorin calcium / Generic mfg., fluorouracil topical / Generic mfg., irinotecan / Generic mfg.
Clinical, Journal: Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma. (Pubmed Central) - Jul 7, 2019
Multimodality neoadjuvant therapy may lead to complete pathologic response in a small number of patients with borderline resectable/locally advanced pancreatic adenocarcinoma. pCR to neoadjuvant therapy does not lead to cure in most cases, and the majority of patients appear to relapse locally or systemically.
- | Clinical, P2 data, Journal: A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer. (Pubmed Central) - Jul 7, 2019
pCR to neoadjuvant therapy does not lead to cure in most cases, and the majority of patients appear to relapse locally or systemically. Celecoxib plus IFL chemotherapy for patients with metastatic CRC is tolerable, but does not appear to increase the efficacy of IFL.
- | leucovorin calcium / generics, fluorouracil / generics
P1 data, Journal: First-in-human phase I study of infusional and bolus schedules of Deflexifol, a novel 5-fluorouracil and leucovorin formulation, after failure of standard treatment. (Pubmed Central) - Jul 6, 2019
Deflexifol is safer and effective in bolus and infusion schedules at higher doses than that permitted by separate infusion of 5-FU and LV. A phase II study evaluating Deflexifol is planned.
- | Clinical, Journal: Can carboplatin or etoposide replace actinomycin-d for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia? (Pubmed Central) - Jul 6, 2019
Carboplatin did not have a satisfactory clinical response rate, likely due to severe hematological toxicity, which postponed chemotherapy. Our results reinforce the preference for Act-d as a second-line agent in patients with low-risk GTN after MTX/FA resistance.
- | leucovorin calcium / generics, fluorouracil / generics
Clinical, Journal: Folate pathway genes linked to mitochondrial biogenesis and respiration are associated with outcome of patients with stage III colorectal cancer. (Pubmed Central) - Jul 6, 2019
A prospective study needs to be conducted to determine if expression of these genes can be used to predict response to leucovorin and other folates that are now being tested in clinical studies. Moreover, there seems to be a link between folate metabolism and mitochondrial biogenesis and respiration that deserves further exploration.
- | Stivarga (regorafenib) / Bayer
Trial completion date, Combination therapy, Metastases: Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 5, 2019
P2, N=181, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Moreover, there seems to be a link between folate metabolism and mitochondrial biogenesis and respiration that deserves further exploration. Trial completion date: Feb 2019 --> Jul 2020
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date, Metastases: IriGen: Individualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 5, 2019
P2, N=47, Completed, Sponsor: Centre Jean Perrin
Trial completion date: Feb 2019 --> Jul 2020 Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Mar 2019 | Trial primary completion date: Jul 2019 --> Mar 2019
- | thioguanine / Generic mfg., azacitidine / Generic mfg.
Enrollment open: AALL15P1: Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement (clinicaltrials.gov) - Jul 5, 2019
P2, N=136, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Mar 2019 | Trial primary completion date: Jul 2019 --> Mar 2019 Suspended --> Recruiting
- | Trial completion date, Trial primary completion date, Metastases: Induction Chemotherapy for Locally Advanced Esophageal Cancer (clinicaltrials.gov) - Jul 5, 2019
P2, N=40, Recruiting, Sponsor: University of Rochester
Suspended --> Recruiting Trial completion date: Jun 2022 --> Jun 2021 | Trial primary completion date: Jun 2019 --> Jun 2020
- |||||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P3 trial, Mismatch repair: CheckMate 8HW: A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Jul 4, 2019
P3b, N=494, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- | Vectibix (panitumumab) / Amgen, Takeda
Clinical, P2 data, Journal: Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. (Pubmed Central) - Jul 4, 2019
P2
During maintenance, arm A had a higher incidence of grade 3 or greater treatment-related adverse events (36 [42.4%] vs 16 [20.3%]) and panitumumab-related adverse events (27 [31.8%] vs 13 [16.4%]), compared with arm B. In patients with RAS wild-type metastatic colorectal cancer, maintenance therapy with single-agent panitumumab was inferior in terms of PFS compared with panitumumab plus fluorouracil-leucovorin, which slightly increased the treatment toxic effects. Clinicaltrials.gov identifier: NCT02476045.
- | leucovorin calcium / generics
Clinical: Regulation of T cell proliferation with drug-responsive microRNA switches. (Pubmed Central) - Jul 4, 2019
...In this work, we developed synthetic microRNA-based genetic systems that are controlled by the pharmaceutical drug leucovorin, which is readily available and safe for prolonged administration in clinical settings...Each control system produced unique functional responses, and combinatorial targeting of multiple receptor subunits exhibited greater repression of cell growth. This work highlights the potential use of drug-responsive genetic control systems to improve the management and safety of cellular therapeutics.
- | leucovorin calcium / generics, methotrexate / generics
Clinical, Journal: How should we manage low-dose methotrexate-induced pancytopenia in patients with rheumatoid arthritis? (Pubmed Central) - Jul 4, 2019
Treatment modalities including folinic acid (leucovorin) either with or without G-CSF result in a shorter recovery/response time compared to other agents. Leucovorin should definitely be considered and applied in rescue therapy for ld-MTX-associated side effects.
- || monalizumab (IPH2201) / AstraZeneca, Innate, Imfinzi (durvalumab) / AstraZeneca
Trial completion date, IO biomarker, Metastases: A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors (clinicaltrials.gov) - Jul 2, 2019
P1/2, N=501, Recruiting, Sponsor: MedImmune LLC
Leucovorin should definitely be considered and applied in rescue therapy for ld-MTX-associated side effects. Trial completion date: Oct 2021 --> Mar 2022
- || Opdivo (nivolumab) / BMS
Trial completion date, Trial primary completion date: CA209-8TT: Pan Tumor Rollover Study (clinicaltrials.gov) - Jul 1, 2019
P4, N=1200, Not yet recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Oct 2021 --> Mar 2022 Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: May 2020 --> Oct 2022
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Enrollment open, Metastases: NAPAN: Second Line Treatment With Nal-IRI and S1 in Pancreatic Cancer (clinicaltrials.gov) - Jul 1, 2019
P2, N=122, Recruiting, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: May 2020 --> Oct 2022 Not yet recruiting --> Recruiting
- || Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
New P2 trial, Metastases: NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer (clinicaltrials.gov) - Jul 1, 2019
P2, N=44, Not yet recruiting, Sponsor: Georgetown University
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion date, Trial primary completion date: Organ Preservation in Early Rectal Cancer Patients (clinicaltrials.gov) - Jul 1, 2019
P2, N=19, Recruiting, Sponsor: Fox Chase Cancer Center
Not yet recruiting --> Recruiting Trial completion date: Mar 2023 --> Mar 2026 | Trial primary completion date: Mar 2019 --> Mar 2022
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Trial primary completion date, Metastases: Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy (clinicaltrials.gov) - Jun 30, 2019
P1, N=20, Not yet recruiting, Sponsor: Washington University School of Medicine
Trial completion date: Mar 2023 --> Mar 2026 | Trial primary completion date: Mar 2019 --> Mar 2022 Trial primary completion date: Jan 2022 --> Aug 2021
- | New P2 trial, Combination therapy: Treatment With Hepatic Arterial Infusion of Oxaliplatin in Combination With Systemic FOLFIRI Chemotherapy and Bevacuzimab in Patients With Liver-only Colorectal Liver Metastases (CRLM): Conversion to Complete Resection in Patients With Initially Inoperable Liver-only CRLM. (clinicaltrials.gov) - Jun 30, 2019
P2, N=49, Not yet recruiting, Sponsor: Rabin Medical Center
- |||| Erbitux (cetuximab) / Eli Lilly, Vectibix (panitumumab) / Amgen
New P4 trial: Randomized study of the detection of mutations by BEAMing technology in advance of the radiological diagnosis of progression in patients with metastatic colorectal cancer and primary tumor in the left colon / rectum Estudio aleatorizado de la detecci (EUDRACT) - Jun 29, 2019
P4, N=80, Ongoing, Sponsor: Fundaci
- | Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Trial suspension: AALL1621: Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jun 28, 2019
P2, N=53, Suspended, Sponsor: Children's Oncology Group
Trial primary completion date: Jan 2022 --> Aug 2021 Recruiting --> Suspended
- | leucovorin calcium / generics
Journal: Development of a Sensitive Chemiluminescence Immunoassay for the Quantification of Folic Acid in Human Serum. (Pubmed Central) - Jun 27, 2019
The method shows good correlation with the FA CLIA product from Beckman Coulter; the equation is y = 0.9618x-0.1434 while the R value is 0.9224. The established method is sensitive, rapid, and accurate which can fully satisfy for the clinical requirement.
- | Enrollment open: Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer (clinicaltrials.gov) - Jun 26, 2019
P2, N=45, Recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
The established method is sensitive, rapid, and accurate which can fully satisfy for the clinical requirement. Not yet recruiting --> Recruiting
- | Zaltrap (ziv-aflibercept IV) / Sanofi, Regeneron
Journal: Posterior Reversible Encephalopathy Syndrome During Treatment with Aflibercept, 5-Fluorouracil, Leucovorin, and Irinotecan for Metastatic Colorectal Cancer. (Pubmed Central) - Jun 26, 2019
Not yet recruiting --> Recruiting No abstract available
- | Avastin (bevacizumab) / Roche
Enrollment open, Trial initiation date, HEOR, Metastases: COLAGE: QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters. (clinicaltrials.gov) - Jun 25, 2019
P3, N=188, Recruiting, Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group
No abstract available Not yet recruiting --> Recruiting | Initiation date: Mar 2019 --> Jun 2019
- | New P2 trial, Metastases: FOLFOXIRI With or Without Intensification for Rectal Cancer (clinicaltrials.gov) - Jun 24, 2019
P2, N=72, Not yet recruiting, Sponsor: CCTU
- || Stivarga (regorafenib) / Bayer
Trial completion, Trial completion date, Trial primary completion date, Metastases: FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer (clinicaltrials.gov) - Jun 24, 2019
P2, N=39, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Not yet recruiting --> Recruiting | Initiation date: Mar 2019 --> Jun 2019 Active, not recruiting --> Completed | Trial completion date: Jul 2020 --> Jun 2019 | Trial primary completion date: Jul 2020 --> Jun 2019
- | leucovorin calcium / generics
Journal: Ocular toxoplasmosis: adverse reactions to treatment in a Brazilian cohort. (Pubmed Central) - Jun 24, 2019
Six percent of ADRs were not previously described, such as taste alteration, constipation/bloating, dyspnoea, sweating and somnolence. Our results suggest a high rate of ADRs to OT classic treatment, which requires careful follow-up in order to identify and treat ADRs early.
- | leucovorin calcium / generics, fluorouracil / generics
Clinical data, Review, Journal: Major innovations and clinical applications of disodium-levofolinate: a review of available preclinical and clinical data. (Pubmed Central) - Jun 21, 2019
Compared with Ca-FA, Na-Lv shows a more favourable efficacy and toxicity profile in terms of overall response rate, progression-free survival, time to progression and occurrence of severe adverse events. Moreover, it allows treatment time to be shortened, decreasing the number of required human resources for drug administration and limiting the occurrence of catheter damage.
- |||| Braftovi (encorafenib) / Pfizer, Mektovi (binimetinib) / Pfizer
Trial completion date, Trial primary completion date, Metastases: BEACON CRC: Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 21, 2019
P3, N=645, Active, not recruiting, Sponsor: Array BioPharma
Moreover, it allows treatment time to be shortened, decreasing the number of required human resources for drug administration and limiting the occurrence of catheter damage. Trial completion date: Jul 2019 --> Aug 2020 | Trial primary completion date: Jul 2019 --> Feb 2019